Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluid...(versity of Alberta and Edmonton Economic...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
Date:8/23/2007
versity of Alberta and Edmonton Economic Development Corporation, TEC Edmonton is committed to providing investors with access to high-growth, advanced-technology opportunities in the form of new inventions, innovations, or early stage ventures created in the Edmonton region. For more information, visit: http://www.TECedmonton.com.
About Microchip Biotechnologies
Microchip Biotechnologies Inc. is an early-stage privately-held company located in Dublin, California that is developing advanced nanofluidic sample preparation and analytical instrumentation for Life Sciences, Applied Sciences, and Diagnostics markets. These solutions are based on MBI's proprietary "NanoBioProcessorTM platform and associated "Microscale-on-Chip-Valves" (MOVTM). More details can be found on the Company's website: http://www.microchipbiotech.com.
'/>"/>
| SOURCE Microchip Biotechnologies Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. TrafficCast secures $2M from Phenomenelle Angels, NEW Capital Fund
2. Perscitus Biosciences secures $250K Commerce loan
3. ProCertus BioPharm secures $2.3M in financing
4. Mirus Bio secures $900K grant to develop research tool
5. BioSystem Development secures angel funding
6. TrafficCast secures $1 million line of credit
7. Medical College secures $9.7M research grant
8. Wausau start up secures $560K for GPS maps
9. Platypus Technologies secures $450K SBIR grant
10. nPoint Secures Second Round of Funding
11. Congresswoman Baldwin secures Federal Funds for UW-Rock County
Post Your Comments:
Breaking Biology Technology:La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert 2La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert 3Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4
[0] La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert [0] Quest Diagnostics Declares Quarterly Cash Dividend[0] Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease[0] Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
Breaking Biology News(10 mins):Hebrew University, American researchers show 'trigger' to stem cell differentiation 2Uniform analyses for clean drinking water in Europe 2Abundance of a look-alike species clouds population status of a million dollar fish 2Abundance of a look-alike species clouds population status of a million dollar fish 3Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet 4690 1Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet 4690 2Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet 4690 3Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet 4690 4Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet 4690 5Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet 4690 6Mixed Marks for Swine Flu Updates 50875 1Mixed Marks for Swine Flu Updates 50875 2Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex 28R 29 12913 1
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |